| MCK |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$9.70 vs. cons $9.55 |
MEDIUM |
| MCK |
Report |
Revenue |
IN-LINE |
pred ~$104.4B vs. cons $104.14B |
MEDIUM |
| MCK |
Report |
Oncology & Multispecialty operating profit |
BEAT |
pred ~$382M vs. cons $375.3M |
MEDIUM |
| MCK |
Guide |
FY27 adjusted EPS (FY27) |
UNCHANGED |
guide $43.80-$44.60 vs. cons $44.25 |
MEDIUM |
| MCK |
Guide |
FY27 free cash flow (FY27) |
BETTER |
guide $4.5-$4.9B vs. cons $4.58B |
MEDIUM |
| MCK |
Guide |
GLP-1 / pricing commentary (FY27) |
UNCHANGED |
guide continued growth / no profit impact vs. cons UNVERIFIED |
LOW |
| MCK |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
LOW |
| MCK |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — mild FY estimate pressure |
LOW |